Betaine/γ-aminobutyric acid (GABA) transporter (BGT1, SLC6A12) is a member of the Na +- and Cl ？-dependent neurotransmitter transporter gene family with a homology to the GABA transporters (GATs), GAT1 (SLC6A1), GAT2 (SLC6A13) and GAT3 (SLC6A11) (HUGO nomenclature). Since antidepressants have been reported to inhibit GABA uptake, we examined those effects on mouse BGT1 (mBGT1) in comparison with other mouse GAT (mGAT) subtypes in the heterologously expressed cell cultures. All antidepressants tested here inhibited the [ 3H]GABA uptake through mBGT1 and mGATs in a rank order of potency with mBGT1 > mGAT1-3. Kinetic analyses for maprotilline, mianserine and trimipramine revealed that they inhibited mBGT1 and mGAT1 noncompetitively, except that mianserine competitively inhibited mBGT1. These results provided a clue to investigate the structure-function relationship of mBGT1 using antidepressants as a tool, leading to the identification of potential candidates for selective and specific inhibitors of mBGT1.
References
[1]
Iversen, L.L. Role of transmitter uptake mechanisms in synaptic neurotransmission. Br. J. Pharmacol 1971, 41, 571–591.
[2]
Yamauchi, A.; Uchida, S.; Kwon, H.M.; Preston, A.S.; Robey, R.B.; Garcia-Perez, A.; Burg, M.B.; Handler, J.S. Cloning of a Na+- and Cl？-dependent betaine transporter that is regulated by hypertonicity. J. Biol. Chem 1992, 267, 649–652.
[3]
Borden, L.A.; Smith, K.E.; Gustafson, E.L.; Branchek, T.A.; Weinshank, R.L. Cloning and expression of a betaine/GABA transporter from human brain. J. Neurochem 1995, 64, 977–984.
[4]
Borden, L.A. GABA transporter heterogeneity: Pharmacology and cellular localization. Neurochem. Int 1996, 29, 335–356.
Dalby, N.O. Inhibition of γ-aminobutyric acid uptake: Anatomy, physiology and effects against epileptic seizures. Eur. J. Pharmacol 2003, 479, 127–137.
[7]
Madsen, K.K.; White, H.S.; Schousboe, A. Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs. Pharmacol. Ther 2010, 125, 394–401.
[8]
Liu, Q.-R.; Lopez-Corcuera, B.; Mandiyan, S.; Nelson, H.; Nelson, N. Molecular characterization of four pharmacologically distinct γ-aminobutyric acid transporters in mouse brain. J. Biol. Chem 1993, 268, 2106–2112.
[9]
Schousboe, A.; Larsson, O.M.; Sarup, A.; White, H.S. Role of the betaine/GABA transporter (BGT-1/GAT2) for the control of epilepsy. Eur. J. Pharmacol 2004, 500, 281–287.
[10]
Langer, Z.S.; Schoemaker, H. Effects of antidepressants on monoamine transporters. Prog. Neuropsychopharmacol. Biol. Psychiat 1988, 12, 193–216.
[11]
Todd, A.J. Neuronal circuitry for pain processing in the dorsal horn. Nat. Rev. Neurosci 2010, 11, 823–836.
[12]
Mico, J.A.; Ardid, D.; Berrocoso, E.; Eschalier, A. Antidepressants and pain. Trends Pharmacol. Sci 2006, 27, 348–354.
[13]
Nakashita, M.; Sasaki, K.; Sakai, N.; Saito, N. Effects of tricyclic and tetracyclic antidepressants on the three types of GABA transporter. Neurosci. Res 1997, 29, 87–91.
[14]
Yamashita, A.; Singh, S.K.; Kawate, T.; Jin, Y.; Gouaux, E. Crystal structure of a bacterial homologue of Na+/Cl？ -dependent neurotransmitter transporters. Nature 2005, 437, 215–223.
[15]
Singh, S.K.; Yamashita, A.; Gouaux, E. Antidepressant binding site in a bacterial homolog of neurotransmitter transporters. Nature 2007, 448, 952–956.
Nyola, A.; Karpowich, N.K.; Zhen, J.; Marden, J.; Reith, M.E.; Wang, D.-N. Substrate and drug binding sites in LeuT. Curr. Opin. Struct. Biol 2010, 20, 415–422.
[18]
Skovstrup, S.; Taboureau, O.; Brauner-Osborne, H.; Jorgensen, F.S. Homology modeling of the GABA transporter and analysis of tiagabine binding. Chem. Med. Chem 2010, 5, 986–1000.
[19]
Kardos, J.; Pallo, A.; Bencsura, A.; Simon, A. Assessing structure, function and druggability of major inhibitory neurotransmitter γ-aminobutyrate symporter subtypes. Curr. Med. Chem 2010, 17, 2203–2213.
[20]
Cherubino, F.; Miszner, A.; Renna, M.D.; Sangaletti, R.; Giovannardi, S.; Bossi, E. GABA transporter lysine 448: A key residue for tricyclic antidepressants interaction. Cell. Mol. Life Sci 2009, 66, 3797–3808.
[21]
Kvist, T.; Christiansen, B.; Jensen, A.A.; Brauner-Osborne, H. The four human γ-aminobutyric acid (GABA) transporters: Pharmacological characterization and validation of a highly efficient screening assay. Comb. Chem. High Throughput Screen 2009, 12, 241–249.
[22]
Sato, T.; Kitayama, S.; Mitsuhata, C.; Ikeda, T.; Morita, K.; Dohi, T. Selective inhibition of monoamine neurotransmitter transporters by synthetic local anesthetics. Naunyn-Schmiedeberg’s Arch. Pharmacol 2000, 361, 214–220.
[23]
Sogawa, C.; Sogawa, N.; Tagawa, J.; Fujino, A.; Ohyama, K.; Asanuma, M.; Funada, M.; Kitayama, S. 5-Methoxy-N,N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter. Toxicol. Lett 2007, 170, 75–82.
[24]
Rudnick, G. What is an antidepressant binding site doing in a bacterial transporter? ACS Chem. Biol 2007, 2, 606–609.
[25]
Barker, E.L.; Kimmel, H.L.; Blakely, R.D. Chimeric human and rat serotonin transporters reveal domains involved in recognition of transporter ligands. Mol. Pharmacol 1994, 46, 799–807.
[26]
Barker, E.L.; Blakely, R.D. Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Mol. Pharmacol 1996, 50, 957–965.
[27]
Lehre, A.C.; Rowley, N.M.; Zhou, Y.; Holmseth, S.; Guo, C.; Holen, T.; Hua, R.; Laake, P.; Olofsson, A.M.; Poblete-Naredo, I. Deletion of the betaine-GABA transporter (BGT1; slc6a12) gene does not affect seizure thresholds of adult mice. Epilepsy Res 2011, 95, 70–81.
[28]
Zhou, Y.; Holmseth, S.; Hua, R.; Lehre, A.C.; Olofsson, A.M.; Poblete-Naredo, I.; Kempson, S.A.; Danbolt, N.C. The betaine-GABA transporter (BGT1, slc6a12) is predominantly expressed in the liver and at lower levels in the kidneys and at the brain surface. Am. J. Physiol. Renal Physiol 2012, 302, F316–F328.
Carninci, P.; Kasukawa, T.; Katayama, S.; Gough, J.; Frith, M.C.; Maeda, N.; Oyama, R.; Ravasi, T.; Lenhard, B.; Wells, C.; et al. The Transcriptional landscape of the mammalian genome. Science 2005, 309, 1559–1563.
[31]
Kitayama, S.; Shimada, S.; Xu, H.; Markham, L.; Donovan, M.D.; Uhl, G.R. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc. Natl. Acad. Sci. USA 1992, 89, 7782–7785.
[32]
Sugimura, M.; Kitayama, S.; Morita, K.; Irifune, M.; Takarada, T.; Kawahara, M.; Dohi, T. Effects of volatile and intravenous anesthetics on the uptake of GABA, glutamate and dopamine by their transporters heterologously expressed in COS cells and in rat brain synaptosomes. Toxicol. Lett 2001, 123, 69–76.
